ARCHIVES

Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment

This article is from The Cancer Letter archive.

Vol. 40 No. 06 | February 7, 2014

Download PDF Visit The Full Archive

Related Articles

NIH Extramural Office Lists Initiatives For Reinvention

January 13, 1995

Two Second-Line CML Drugs Work Front-Line, Studies Find

January 29, 2010

First CCOP 3 Returns In; Payline Not Yet Determined; Goes to NCAB On Jan. 30

January 26, 1990

Socio-Economic Factors, Access To Care, Associated With More Aggressive Cancers

April 27, 2007

Contracts Awarded For $30 Million Heavy Smokers Clinical Trials

October 10, 1986

CCOP Recompetition Approved, “Institutionalized;” Board Okays Concept For Eight Minority CCOPs

February 3, 1989